News from morphotek inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Feb 03, 2016, 09:00 ET
Morphotek Inc. Logo

Morphotek Announces Collaboration with Mayo Clinic to Apply Its Folate Receptor Alpha Diagnostic Assays in a Phase II Clinical Trial in Triple-Negative Breast Cancer

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it is collaborating with researchers Keith L. Knutson, Ph.D. in the...

Dec 16, 2015, 09:00 ET
Morphotek Inc. Logo

Morphotek®, Inc. Announces An Agreement With Biocare Medical, LLC To Develop And Commercialize A Diagnostic Kit For Detection Of Mesothelin In Malignant Tissues

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into a second collaboration and license agreement with...

Dec 07, 2015, 09:00 ET
Morphotek Inc. Logo

Morphotek Announces Phase 1 Results From MORAb-022-001 Trial In Healthy Subjects And Patients With Mild-To-Moderate Rheumatoid Arthritis

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today results from Study MORAb-022-001, a single-dose, dose-ascending,...

Dec 03, 2015, 09:00 ET
Morphotek Inc. Logo

Morphotek Announces Collaboration Agreement With University Of Wisconsin-Madison To Study The Immunosuppressive Effects Of CA125 Tumor Antigen On Immune-Based Therapies For Ovarian Cancer

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it entered into a collaborative research agreement with University of...

Nov 18, 2015, 09:00 ET
Morphotek Inc. Logo

Morphotek®, Inc. Announces Initiation Of Amatuximab Study In First-Line, Unresectable, Malignant Pleural Mesothelioma Patients

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has enrolled the first patient in the randomized, double-blind...

Nov 17, 2015, 09:00 ET
Nov 09, 2015, 09:00 ET
Morphotek Inc. Logo

Morphotek®, Inc. Announces A License Agreement With Blaze Bioscience, Inc. For The Development Of Novel Oncology Imaging Technology

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has entered into a license agreement with Blaze Bioscience, Inc. of...

Oct 26, 2015, 09:00 ET
Morphotek Inc. Logo

Morphotek®, Inc. Presents Preclinical Findings At ESGO 19 On The Potential Immunosuppressive Effects Of The CA125 Tumor Antigen On Farletuzumab, An Investigational Anti-Folate Receptor Alpha Antibody

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has presented preclinical data showing the immunosuppressive...

Mar 30, 2015, 09:00 ET

Morphotek®, Inc. Announces Initiation Of Farletuzumab Study In Patients With First-Relapsed, Platinum-Sensitive Ovarian Cancer With Low Levels Of The Immunosuppressive CA125 Tumor Antigen

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has enrolled the first patient in a randomized, double-blind study of...

Oct 09, 2013, 09:05 ET

Morphotek, Inc. Announces Initiation Of A New MORAb-004 Phase I Study In Pediatric Patients With Relapsed/Refractory Solid Tumors

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the Children's Oncology Group (COG) has opened enrollment in a Phase 1...

Jul 03, 2013, 09:00 ET

Morphotek Achieves LEED® Certification For New Pilot Plant

Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has achieved LEED® certification for its new 60,000-square-foot...

Jun 25, 2013, 09:30 ET

Morphotek, Inc. Announces Initiation Of A Phase I Study For MORAb-066

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the Sarah Cannon Research Institute in Nashville, Tennessee has opened...

Feb 04, 2013, 09:00 ET

Morphotek Inc. Pilot Plant Receives 2013 Facility of the Year Award

 Morphotek® Inc., a subsidiary of Eisai Inc., announced today that its recently opened 60,000-square-foot pilot plant for the...

Jan 10, 2013, 18:30 ET

Morphotek Announces Top-Line Results of a Phase III Study of Farletuzumab in Patients With Relapsed Platinum-Sensitive Epithelial Ovarian Cancer

 Morphotek® Inc., a wholly-owned subsidiary of Eisai Inc., announced today top-line results from a Phase III study of its investigational...

Nov 12, 2012, 09:00 ET

FDA Grants Orphan Drug Status To Morphotek's Amatuximab (MORAb-009)

 Morphotek® Inc., a subsidiary of Eisai Inc., announced today that the United States Food and Drug Administration (FDA) has granted orphan...

Aug 27, 2012, 09:00 ET

Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Metastatic Soft Tissue Sarcoma

 Morphotek®, Inc. announced today that it has commenced a multi-center, Phase II study evaluating the safety and efficacy of MORAb-004...

Aug 14, 2012, 14:00 ET
Morphotek, Inc., a wholly-owned subsidiary of Eisai Co., Ltd., commemorates the opening of its newly constructed pilot manufacturing plant in Exton, PA. Pictured left to right are Christopher Molineaux, President, Pennsylvania Bio; Hideki Hayashi, Deputy President and Chief Product Creation Officer, Eisai Co., Ltd.; Nick Nicolaides, President and CEO, Morphotek, Inc.; Haruo Naito, President and CEO, Eisai Co., Ltd.; Philip Sass, Executive Vice President and COO, Morphotek, Inc.; Joye Bramble, Vice President, Pilot Plant Operations, Morphotek, Inc.; Pennsylvania State Senator Andy Dinniman; Eli Avila, Pennsylvania Secretary of Health, and Luigi Grasso, Chief Scientific Officer, Morphotek, Inc.  (PRNewsFoto/Morphotek(R), Inc.)

Morphotek®, Inc. Opens 60,000-square-foot Manufacturing Plant

 Morphotek®, Inc., a wholly-owned subsidiary of Eisai Co., Ltd., today celebrated the grand opening of a new pilot manufacturing plant...

May 30, 2012, 09:00 ET

Morphotek® Earns Prestigious Award For Innovation In Assay Development

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that The American Association of Pharmaceutical Scientists (AAPS) has...

Apr 16, 2012, 09:00 ET

Morphotek®, Inc. Announces Initiation of MORAb-004 Phase 2 Study in Metastatic Colorectal Cancer

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that it has commenced a multi-center, Phase II study evaluating the safety...

Mar 27, 2012, 09:00 ET

Morphotek®, Inc. Announces Completion of Enrollment in the FAR-131 Trial for Relapsed Ovarian Cancer

 Morphotek®, Inc., a subsidiary of Eisai Inc., announced today it has completed enrollment of the FAR-131 clinical trial. The study is a...